Trials / Unknown
UnknownNCT04966611
Anlotinib for Esophageal Cancer (AFEC)
A Real World Study on the Effect of Single or Combined Treatment of Anlotinib on Survival and Prognosis of Advanced Esophageal Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Anyang Tumor Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced esophageal cancer in the real world, and to summarize the treatment experience of a wide range of people.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | This is an observational study |
Timeline
- Start date
- 2021-07-15
- Primary completion
- 2023-07-15
- Completion
- 2024-07-15
- First posted
- 2021-07-19
- Last updated
- 2021-07-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04966611. Inclusion in this directory is not an endorsement.